Janes Acquires Global Platforms & Systems business from Avascent

Montagu

24th November 2020

Janes has today announced an agreement to acquire the defence market analytics business – also known as Global Platforms and Systems (“GPS”) – from Avascent to support its industry intelligence solutions and enhance the offering it provides to customers.

This acquisition comes as we continue to build on the momentum we have created since becoming an independent business and ensures that we will continue to deliver the objective open-source intelligence and analytics that our customers rely upon.

Blake Bartlett, CEO of Janes

“I’m delighted to announce the acquisition of GPS from Avascent – it’s a great addition to our portfolio of trusted open-source defence intelligence solutions and allows us to enhance our position as the leading provider of defence market forecasts worldwide,” said Blake Bartlett, CEO at Janes. “This acquisition comes as we continue to build on the momentum we have created since becoming an independent business and ensures that we will continue to deliver the objective open-source intelligence and analytics that the world of defence and security relies upon.”

“This deal brings a highly complementary capability into the Janes ecosystem of connected data that our customers trust in their most critical decisions,” said Doug Dixon, President of Aerospace and Defence Industry at Janes. “We’re focused on getting our customers the right data in the right structure to underpin the analytics they need to operate in the modern national security environment.”

“In Janes, we have found a partner that can take the GPS business to the next level while we continue to focus and invest in our core strategy consulting business,” said Steve Irwin, President of Avascent. “Clients who have come to rely on GPS and its custom features will experience no change in the quality of the product or the responsiveness of the client service. Indeed, clients who have wanted closer integration between GPS and other data resources can now look forward to the prospect of more powerful tools to support their strategy, corporate development, and business development efforts.”

The deal between Janes and Avascent also includes a collaboration agreement through which the two firms can pursue opportunities where their joint capabilities will provide clients with unparalleled insights and advice on critical defence and security issues.

Janes expects completion of the acquisition in January 2021 subject to customary conditions.

Categories: News

Tags:

Eurazeo announces the completion of the sale of its stake in Iberchem

Eurazeo

Paris, November 24, 2020

Eurazeo Capital has announced today the completion of the sale of the entire share capital of Iberchem in which Eurazeo has been a shareholder since July 2017, to Croda International Plc (LON: CRDA).

Over the last three years, Iberchem has significantly reinforced its position as a leading global producer of fragrances and flavours focusing on local and regional brands in high-growth international markets. Thanks to its strategic positioning, the company combined a best-in-class organic growth of +15% per year sales over the last 10 years and targeted M&A, with the support of Eurazeo network, notably in China and Malaysia.

Transaction sales proceeds for Eurazeo and its investors partners total € 564m and € 383m for Eurazeo only, representing a return on its initial investment of 2.1x and an Internal Rate of Return (IRR) of approximately 25%. This price is more than 30% above the one reflected in our NAV as of 30 June 2020 (or about 1.25€ by Eurazeo share).
Ramón Fernández, Founder and Chief Executive Officer, Iberchem, said:
“ It has been a great pleasure to work with Eurazeo teams during these last years. We have been able to take advantage of their professional experiences and their wide network, as well as their in-depth understanding of Iberchem’s model specificities and strengths. ”

Marc Frappier, Managing Partner, Head of Eurazeo Capital, said:
“We would like to thank the management team and employees of Iberchem, led by Ramón Fernández, CEO and founder, for our fantastic partnership over the last 3 years. We were delighted to help them further accelerate their global growth story. We wish them all the success they deserve in the next phase of their journey with the support of Croda, the perfect partner for Iberchem’s future development.”

About Eurazeo
• Eurazeo is a leading global investment group, with a diversified portfolio of €18.8 billion in Assets Under Management, including €13.3 billion from third parties, invested in over 430 companies. With its considerable private equity, real estate and private debt expertise, Eurazeo accompanies companies of all sizes, supporting their development through the commitment of its nearly 300 professionals and by offering deep sector expertise, a gateway to global markets, and a responsible and stable foothold for transformational growth. Its solid institutional and family shareholder base, robust financial structure free of structural debt, and flexible investment horizon enable Eurazeo to support its companies over the long term.

• Eurazeo has offices in Paris, New York, Sao Paulo, Seoul, Shanghai, London, Luxembourg, Frankfurt, Berlin and Madrid
• Eurazeo is listed on Euronext Paris.
• ISIN: FR0000121121 – Bloomberg: RF FP – Reuters: EURA.PA

EURAZEO CONTACTS

HEAD OF INVESTOR RELATIONS

e–mail: pbernardin@eurazeo.commail: pbernardin@eurazeo.com
Tel: +33 (0)1 44 15 16 76

VIRGINIE CHRISTNACHT
HEAD OF COMMUNICATIONS

e–mail: mail: vchristnacht@eurazeo.comvchristnacht@eurazeo.com
Tel: +33 1 44 15 76 44

DAVID STURKEN
MAITLAND/AMO
e-mail: dsturken@maitland.co.uk
Tel: +44 (0) 7990 595 913

Categories: News

Tags:

Ardian enters into exclusive negotiations to support the development of Inovie, the leading independent medical diagnostic provider in France

Ardian

24 November 2020 Buyout Paris, France

Paris, November 24th, 2020 – Inovie, the leading independent medical diagnostic provider in France, and Ardian, a world-leading private investment house, announce today that they have entered into exclusive negotiations for the acquisition of a minority stake by Ardian in Labosud, Inovie group’s lead company. The entry was approved by a very large majority of the group’s shareholding biologists (93% of votes in favor), and who will reinvest significant capital as part of the transaction, during a General Assembly dated November 19th, 2020. The transaction remains subject to the consultation processes of the relevant Labosud employee representative bodies in accordance with applicable law.

Founded in 2010, Inovie has undergone significant external growth to become the leading independent medical diagnostic provider in France and a key player across Southern and Central France specifically. With a strong local footprint of 19 multi-site laboratories spread over five key regions (Occitanie, Provence-Alpes-Côte-d’Azur, Nouvelle Aquitaine Auvergne Rhône Alpes and Centre Val de Loire), Inovie’s biologists and 4,500 employees deliver high-standard clinical pathology testing to more than 46,000 patients daily. Inovie has also played a leading role in innovation, notably through their work in four areas of specialty: fertility (Inovie Fertilité), genomics (Imagenome), anatomopathology (Inopath) and veterinary services (Inovie Vet).

As part of the partnership with Ardian, Inovie will maintain independence and further develop its renowned model. The management team will remain in charge of business operations, and the biologists will retain a majority stake in Labosud’s as well as and voting rights, whilst continuing to be the cornerstone of Inovie’s operating excellence.

Ardian’s investment aims to make Inovie a leader in an increasingly competitive market, and one of the best-positioned companies to face current and future public health challenges. With Ardian as a shareholder, Inovie will be able to pursue an ambitious external growth and diversification strategy based on the development of its specialties, an acceleration of its digital strategy, and international expansion.

Georges Ruiz, President of Inovie, said: “To be able to keep up with future challenges in clinical pathology, notably in terms of development, diversification and innovation, we had to evolve our model and find new resources whilst staying close to our roots. We are very pleased to have built a project for the future with Ardian, which stays true to our core values relating to better supporting our patients in the course of their care by bringing together the best practitioners in clinical pathology. This is thanks to the dedication and competence of our teams in their daily work.“

Philippe Poletti, CEO of Ardian France, Member of the Executive Committee and Head of Ardian Buyout: “We are honored that Inovie’s biologists have placed their trust in Ardian and share our ambition for the development plan that we have built over the past 9 months with Georges Ruiz, the President of Inovie, and his teams.”

Nicolas Darnaud, Managing Director in Ardian Buyout team, complements: “In a few years’ time, Inovie was able to continuously provide their essential contribution to clinical pathology in France, notably through the delivery of their specialized centres, which are a major asset in an increasingly competitive market. With our partnership, we will begin a new chapter in the group’s development by leveraging its existing strengths and supporting its principles and core values, as well as contributing new resources. We believe that by doing this, we will fully equip Inovie to face the challenges in clinical pathology for the years to come.”

LIST OF PARTICIPANTS

  • Ardian

    • Nicolas Darnaud, Edouard Level, Edmond Delamalle, Pierre Casas
    • Buyer M&A advisors: Rothschild & Co. (Laurent Baril, Robert Rozemulder, Youssef Bouallou, Pierre-Yves Lebot), Edmond de Rothschild Corporate Finance (Pierre Boscher, Arnaud Petit, Aurélien Bouvier, Victor Auguin-Rougier)
    • Buyer legal advisors : Latham & Watkins (Gaëtan Giannasso, Michael Colle (corporate), Xavier Farde, Carla-Sophie Imperadeiro (financing), Xavier Renard, Thomas Claudel (structuring))
    • Buyer strategic DD: Bain & Company (Jérôme Brunet, Agnès Houdaille, Ghofrane Maaroufi)
    • Buyer financial DD: EY (Hervé Jauffret, Elsa Abou Mrad, Vincent Magaud)
    • Buyer operational DD: EY (Olivier Sibenaler, Olivier Nicolle, Paul-Louis Royer)
    • Buyer legal, tax, labor DD: EY (Virginie Lefebvre-Dutilleul, Christine Salès (legal), Lionel Benant, Nevenna Teodorova (tax), Sophie Muyard, Taïna Celestin (labor))
    • Buyer ESG DD: Indefi (Emmanuel Parmentier, Charlotte Salmon)
    • Buyer insurance DD: Siaci Saint Honoré (Pierre de Rochebouët, Anne Rougerie)
  • Inovie

    • Inovie’s Executive Committee: Georges Ruiz, Sébastien Floret, Dominique Forte, Thomas Hottier, Xavier Huc, Benoît Ponseillé
    • Vendor M&A advisor: BNP Paribas (Marc Walbaum, Alexandre Greco, Xavier Caron, Hui Zhao)
    • Vendor legal advisor: Weil Gotshal & Manges (Jean Beauchataud, Romain Letard, Michaël Koubi)
    • Vendor financial DD: PwC (Philip Dykstra, Frédéric Spielrein, Pierre-Mikhaël Voyer)
    • Vendor legal DD: Weil, Gotshal & Manges (Jean Beauchataud, Romain Letard, Michaël Koubi)
    • Vendor tax, labor DD: PwC (Jean-Philippe Brillet, Mathieu Echallier, Jihanne Flegeau-Kihal (fiscal), Bernard Borrely, Pauline d’Humières (social))
    • Management financial advisor: Callisto Finance (Vincent Aymé, Tancrède Caulliez)

ABOUT ARDIAN

Ardian is a world-leading private investment house with assets of US$100bn managed or advised in Europe, the Americas and Asia. The company is majority-owned by its employees. It keeps entrepreneurship at its heart and focuses on delivering excellent investment performance to its global investor base.
Through its commitment to shared outcomes for all stakeholders, Ardian’s activities fuel individual, corporate and economic growth around the world.
Holding close its core values of excellence, loyalty and entrepreneurship, Ardian maintains a truly global network, with more than 700 employees working from fifteen offices across Europe (Frankfurt, Jersey, London, Luxembourg, Madrid, Milan, Paris and Zurich), the Americas (New York, San Francisco and Santiago) and Asia (Beijing, Singapore, Tokyo and Seoul). It manages funds on behalf of around 1,000 clients through five pillars of investment expertise: Fund of Funds, Direct Funds, Infrastructure, Real Estate and Private Debt. Follow Ardian on Twitter @Ardian

Press contacts

ARDIAN – Headland

Gregor Riemann

griemann@headlandconsultancy.com +44 (0)7920 802 627

Categories: News

Tags:

Spring Marketing Capital invests in Purplle from its maiden fund

Verlinvest

Purplle is backed by Blume Ventures, IvyCap Ventures, JSW ventures – and last year it raised more than $30 million from Goldman Sachs and Verlinvest.

Branding and marketing-focused fund Spring Marketing Capital has made its first investment of $1 million from its maiden fund in Purplle, a beauty e-commerce platform.

Purplle is backed by Blume Ventures, IvyCap Ventures, JSW ventures.

It raised more than $30 million last year from Goldman Sachs and Verlinvest, the Belgian investment holding company, in its Series C funding round.

Launched in 2011, Purplle has a revenue run rate of around Rs 500 crore as on date and is earnings before interest, tax, depreciation and amortisation (Ebitda) break even, said Manish Taneja, co-founder, Purplle.

According to Taneja, the company might soon look to expand to other countries. “Unlike other creative agencies that work ..
It has some startups founders and other GPs as other backers.

Launched last year by Raja Ganapathy, the former chief marketing officer of Sequoia Capital India, along with Vineet Gupta, ex-group chief executive of DDB Mudra and Arun Iyer, former chairman of Lowe Lintas, Spring looks to invest in early-stage, consumer-facing startups.

“We have spent a lot of time with the Purplle founders and are very impressed with their vision to create an online beauty platform out of India.  ..

People in this post: Arjun Anand

Portfolio companies in this post: Purplle

Categories: News

Tags:

Janes Acquires Global Platforms & Systems business from Avascent

Montagu

Janes has today announced an agreement to acquire the defence market analytics business – also known as Global Platforms and Systems (“GPS”) – from Avascent to support its industry intelligence solutions and enhance the offering it provides to customers.

This acquisition comes as we continue to build on the momentum we have created since becoming an independent business and ensures that we will continue to deliver the objective open-source intelligence and analytics that our customers rely upon.

Blake Bartlett, CEO of Janes

“I’m delighted to announce the acquisition of GPS from Avascent – it’s a great addition to our portfolio of trusted open-source defence intelligence solutions and allows us to enhance our position as the leading provider of defence market forecasts worldwide,” said Blake Bartlett, CEO at Janes. “This acquisition comes as we continue to build on the momentum we have created since becoming an independent business and ensures that we will continue to deliver the objective open-source intelligence and analytics that the world of defence and security relies upon.”

“This deal brings a highly complementary capability into the Janes ecosystem of connected data that our customers trust in their most critical decisions,” said Doug Dixon, President of Aerospace and Defence Industry at Janes. “We’re focused on getting our customers the right data in the right structure to underpin the analytics they need to operate in the modern national security environment.”

“In Janes, we have found a partner that can take the GPS business to the next level while we continue to focus and invest in our core strategy consulting business,” said Steve Irwin, President of Avascent. “Clients who have come to rely on GPS and its custom features will experience no change in the quality of the product or the responsiveness of the client service. Indeed, clients who have wanted closer integration between GPS and other data resources can now look forward to the prospect of more powerful tools to support their strategy, corporate development, and business development efforts.”

The deal between Janes and Avascent also includes a collaboration agreement through which the two firms can pursue opportunities where their joint capabilities will provide clients with unparalleled insights and advice on critical defence and security issues.

Janes expects completion of the acquisition in January 2021 subject to customary conditions.

Categories: News

Tags:

BGF invests in North East Tech Business

BGF

BGF has completed a multi-million pound investment for a minority shareholding in a Teesside-headquartered Engineering Information Management (EIM) software company, Datum360, to accelerate growth and address significant market demand.

Datum360’s software platform connects disparate systems, providing a trusted data backbone which manages the life cycle of critical engineering and asset management data for a range of blue-chip customers from the fields of energy, mining, utilities, road and rail infrastructure.

The fast growth technology company was founded by CEO Steve Wilson, alongside CTO Dave Mitchell and CFO James Michael. The management team have a combined 50 years’ experience working within large engineering and design firms where they cultivated a deep understanding of data management in major capital projects.

The pioneering North East company has offices in Australia and plans to open a US base in 2021. It has a global reach and is undertaking projects in North America, Europe, Asia and Australia.

Datum360 counts organisations such as BP, Total and BHP among its customers. BGF’s investment will help to unlock its expansion and allow the business to build on the fast growth it has experienced to date.

Commenting on the investment, CEO Steve Wilson said “Datum360 has built a reputation for delivering, at speed and globally, our cloud based Connected Data platform for Engineering Information. Working with energy, mining, utilities and infrastructure clients, we are excited to see the demand for data become more distinct and more urgent. Our capability delivers the critical data foundation and backbone which underpins our clients evolving approach to BIM and building and maintaining their Digital Twins.”

“BGF’s investment team and their expertise in supporting the scale-up of technology businesses like ours is invaluable to the next stage of our growth. Having first met BGF in September this year, we have been impressed with the pace to get the deal to completion. The BGF team were quick to understand our business and market opportunity and we look forward to working together to achieve our shared ambitions.”

BGF opened a Newcastle office in 2018 and has invested in a number of innovative fast-growing North East companies, such as Sunderland-based SaleCycle – a behavioural marketing technology company – and Alnwick-headquartered Arcinova, a life sciences business.

Chris Boyes from BGF led the deal. Chris said: “Datum360 is a fine example of a North East business with a market-leading product which has significant global potential. With the growth plan and opportunity for the business clear, we were able to deploy capital very quickly. We already have a number of successful investments in the North East and are looking to back more businesses in the region.”

“We recognise that business owners are trading in a very tough economy and we believe that equity investment can be a solution for supporting progressive entrepreneurs’ growth ambitions, as well as playing a vital role in driving economic recovery.”

 

Categories: News

Tags:

Europe is on its way to quantum leadership: IQM raises €39 M in Series A funding

OpenOcean

ESPOO, Finland, 10th November 2020

IQM Quantum Computers (IQM), the European leader in building superconducting quantum computers, today announced that it has raised €39 M in Series A funding, bringing the total amount of funding raised to date to €71 M.

This ranks among the highest fundraising rounds by a European deep-tech startup within a year. MIG Fonds has led this round, with participation from all existing investors including Tesi, OpenOcean, Maki.vc, Vito Ventures, Matadero QED. New investors Vsquared, Salvia GmbH, Santo Venture Capital GmbH, and Tencent, have also joined this round.

“IQM has a strong track record of research and in achieving high growth. They continue to attract the best global talent across functions and have exceeded their hardware and software milestones. We are thrilled to lead this round and continue to support IQM as the company accelerates its next phase of business and hardware growth,” said Axel Thierauf, Partner at MIG Fonds, and Chairman of the Board of IQM.

Since 2019, IQM has been among the fastest-growing companies in the quantum computing sector and already has one of the world’s largest quantum hardware engineering teams. This funding will be used to accelerate IQM´s hardware development and to co-design application-specific quantum computers. A significant part of the funding will also be used to attract and retain the best global talent in quantum computing, and to establish sales and business development teams.

”Today’s announcement is part of our ongoing Series-A funding round. I am extremely pleased with the confidence our investors have shown in our vision, team, product, and the ability to execute and commercialize quantum computers. This investment also shows their continued belief in building the future of quantum technologies. This is a significant recognition for our fantastic team that has achieved all our key milestones from the previous round. We’re just getting started,” said Jan Goetz, CEO of IQM.

“It is impressive to be a part of the IQM journey and see the progress of their technology. We’re proud to see another startup from Finland making a global impact. IQM will have a lasting impact on the future of computing, and consequently will help solve some of the global challenges related to healthcare, climate change and development of sustainable materials among many others,” said Juha Lehtola, Head of Direct VC Investments at Tesi (Finnish Industry Investment).

IQM delivers on-premises quantum computers for research laboratories and supercomputing centers. For industrial customers, IQM follows an innovative co-design strategy to deliver quantum advantage based on application-specific processors, using novel chip architectures and ultrafast quantum operations. IQM provides the full hardware stack for a quantum computer, integrating different technologies, and invites collaborations with quantum software companies.

“We want to invest in deep technology startups that shape the future and advance society. IQM is the perfect example of a company that is on top of its game; their work on quantum computing will make an impact for generations to come,” said Herbert Mangesius, Founding Partner at Vsquared and Vito Ventures.

While quantum computing is still under development, governments and private organizations across the world are investing today to retain their competitive edge and become quantum-ready for the future.

The next decade will be the decade of quantum technology, and we will see major breakthroughs with real-world applications using quantum computers in healthcare, logistics, finance, chemistry and beyond.

About IQM Quantum Computers:

IQM is the European leader in superconducting quantum computers, headquartered in Espoo, Finland. Since its inception in 2018, IQM has grown to 70+ (TBC) employees and has also established a subsidiary in Munich, Germany, to lead the co-design approach. IQM delivers on-premises quantum computers for research laboratories and supercomputing centers and provides complete access to its hardware. For industrial customers, IQM delivers quantum advantage through a unique application-specific co-design approach. IQM has also received a €3.3 M grant from Business Finland and has been awarded a €15 M equity investment from the EIC Accelerator program.

For more information, visit www.meetiqm.com.

Registered office:

IQM Finland Oy
Keilaranta 19
02150 Espoo
FINLAND
www.meetiqm.com

Media Contact:

Raghunath Koduvayur

Head of Marketing and Communications

Raghunath@meetiqm.com

+358504876509

Additional investor quotes:

” We are proud once again to invest in IQM. Quantum computing processors are on the edge of our core scope of investing in scalable B2B software businesses, but this opportunity was too big to miss. We need a strong quantum eco-system to address the next generation of data-intensive computations, which cannot be created without the fastest and most robust quantum machines for real world applications provided by IQM. This is where IQM can be the step change that will foster the future of the industry,” said Ekaterina Almasque, Venture Partner at OpenOcean.

“IQM is a game-changer — a company that can play a leadership role in quantum computing, and one that will have a huge positive impact across the world. Quantum computers will also help us with our sustainability goals. We are thrilled to continue to support their ambitious vision,” said Ilkka Kivimäki, Partner at Maki.vc.

“IQM’s technical innovation, world-class scientific team and drive in building quantum computers have made them a European leader in the quantum computers field. We look forward to supporting them in commercializing quantum computing and achieving more milestones in future,” said Dr Ling Ge, Chief European Representative at Tencent.

“IQM’s seasoned technical and commercial team, long-term focus on quantum technology for global markets fits in well with our new fund’s focus areas. They have created leading technology from Europe and we are proud to join this round,” said Helmut Jeggle, Founding Partner and Managing Director at Salvia GmbH.

”We believe in partnering with exceptional founders building the next generation of deep-tech global businesses. IQM has done a fabulous job in attracting the best talent and are solving real problems with their innovative approach. Quantum computing is definitely the future,” said Johannes Froehling, Deeptech investment activities at Matadero QED.

About the investors:

MIG Fonds: https://www.mig.ag

OpenOcean: https://openocean.vc

Maki.vc: https://maki.vc

Tesi (Finnish Industry Investment Ltd): www.tesi.fi

Vito Ventures: http://vito.vc

VSquared Ventures: https://www.vsquared.vc

Tencent: https://www.tencent.com/

You can also download our press releases here:

IQM Series A press release – French

IQM Series A press release – Finnish

IQM Series A press release – German

IQM Series A press release – English

IQM Series A press release – Swedish

Categories: News

Tags:

AlgoTherapeutix raises €12M to take ATX01 into clinical development in chemotherapy-induced peripheral neuropathy

Omnes Capital

France-based biotechnology company AlgoTherapeutix, the developer of an innovative topical treatment for chemotherapy-induced peripheral neuropathy (CIPN), has raised €12M in a Series A round led by Bpifrance through its InnoBio 2 fund with co-investor Omnes. Existing and new business angel investors, also significantly participated in this financing round. The proceeds will be used to fund the clinical development of its lead candidate ATX01 up to clinical proof of concept.

Over the last two years, AlgoTherapeutix took ATX01 from exploratory prototype to final formulation, established its pharmacological profile, conducted a full pre-clinical toxicology package, and scaled-up manufacturing to enable clinical supply production. In parallel, AlgoTx firmed-up ATX01’s development pathway via a pre-IND consultation with the FDA and obtained an Orphan Drug Designation from the FDA to explore ATX01’s activity in erythromelalgia. ATX01 is due to enter Phase I clinical trials in early 2021.

Inspired by clinical experience at a specialized pain treatment center, AlgoTherapeutix’s ATX01 targets topical treatment of CIPN by repositioning amitriptyline into a suitable topical formulation. The body of data from ATX01’s pre-clinical development now provides the pharmacological explanation for encouraging exploratory clinical observations with a precursor formulation published in early 2019.

Over half of cancer patients treated with chemotherapy develop CIPN and experience sensory symptoms and pain in the hands and feet:  loss of sensitivity, tingling, burning, cold and intense pain can persist for months to years after treatment. CIPN can prevent patients from walking or using their hands, thus deeply affecting their quality of life.

CIPN is found in over two million patients in the US and Europe, a leading cause for modification or interruption of chemotherapy. To this date, no therapeutic approach has offered a satisfactory response for patients and their caregivers, oncologists and pain specialists.

Stéphane Thiroloix, Founder & CEO of AlgoTherapeutix, says: “I am thrilled that such high-profile partners as Bpifrance and Omnes decided to support ATX01’s development journey towards a genuine relief for countless patients around the world.”

Thibaut Roulon, Investment Director at Bpifrance commented: “CIPN is a considerable unmet medical need. We are enthusiastic about AlgoTherapeutix’s innovative and pragmatic approach, which could significantly improve the quality of life for many cancer patients”.

“The AlgoTherapeutix team displayed scientific and operational strength in the early development of ATX01 and we are confident in their ability to establish the product’s clinical efficacy and safety going forward”, stated Claire Poulard, Principal at Omnes Capital.

Categories: News

Tags:

Opteran Secures £2.1m in Seed Funding to Solve Autonomy Using Natural Intelligence Inspired by Insects

IQ Capital

Sheffield UK, 24 November 2020 – Opteran, the Natural Intelligence company, has raised £2.1 million in seed funding. Opteran will use the funds to pioneer its radical lightweight, low cost silicon-based approach to autonomy called Natural Intelligence and expects its technology will significantly expand the potential addressable market for autonomy in machines and robotics.

The round was led by IQ Capital with Episode1, Join and Seraphim Capital also participating. Following on from a pre-seed round from the Connecting Capabilities Fund of the British Business Bank, the latest funding round also includes angel investors and a CCF grant, a part of the Northern Triangle Initiative .

Opteran is a University of Sheffield spin-out based on eight years of research by Professor James Marshall and Dr. Alex Cope into insect brains as part of the Green Brain and Brains on Board projects. Although insects have smaller brains, they are still capable of sophisticated decision making and navigation using optic flow to perceive depth and distance. This is a far more efficient, robust and transparent way to achieve autonomy than current Deep Learning techniques enabling Opteran to reverse-engineer insect brains to produce algorithms requiring no data centre or extensive pre-training. It means Opteran can mimic tasks such as seeing, sensing objects, obstacle avoidance, navigation and decision making and in a recent trial they were able to control a sub-250g drone, with complete onboard autonomy, using fewer than 10,000 pixels from a single low-resolution panoramic camera.

Weighing approximately 30g, and integrating Opteran technology drawing less than a watt of power, the Opteran Development Kit (ODK) will enable the technology to be integrated into a wide variety of applications in the robotics market, which is expected to grow to $77 billion by 2022(1). Opteran’s technology will transform the use case for a wide variety of autonomous vehicles, drones, mining robots and even off-planet vehicles, as it will enable real-time autonomous decision-making. In the next 18 months Opteran will use this seed funding to build out functionality in the algorithms and chipsets, including launching Opteran Sense for obstacle avoidance and reactive navigation, Opteran Direct for SLAM, Opteran Decide for autonomous decision-making, and Opteran See – a 360 degree camera. It will also look to expand its engineering and commercial team, and is currently launching a Development Kit to enable partners to embed its technology in their applications.

David Rajan, CEO, Opteran, commented: “2021 will be the year when Natural Intelligence will challenge deep learning in solving some of the most fundamental short-comings in autonomous applications and this funding round will set Opteran on a path to be at the forefront of this next wave. Already in a position to demonstrate the technology, we are confident that Natural Intelligence will become highly sought after as the way to deliver lightweight, low-cost and effective autonomy in a radically new way that will open up huge growth opportunities for robotics.”

Ed Stacey, partner at IQ Capital said: “We are hugely excited to be working with Opteran, as Natural Intelligence adds a whole new dimension that will transform the way in which we create intelligent machines – starting with the design of more efficient silicon brains for robots and autonomous vehicles. We are delighted to be supporting them at the start of their commercial journey and are excited to see the technology they create and the role it plays in the wider AI market in the years ahead.”

Categories: News

Porotech launches groundbreaking micro-LED product

IQ Capital

4 November, 2020 – University of Cambridge spin-out Porotech has today announced the launch of its first product based on its breakthrough gallium nitride (GaN) production technique that is set to transform the electronics industry. The company has launched the world’s first commercial native red LED epiwafer for micro-LED applications.

Micro-LED display technology offers a huge improvement on standard display panels due to its optimum brightness, efficiency and image definition, as well as improved lifetime. These benefits are crucial for near-to-eye applications such as augmented reality (AR) and head-mounted displays – a market predicted to be worth tens of billions of dollars over the next five years. They are also key for a range of other applications – from large area displays and TVs to mobile phones and wearable devices such as smartwatches. But, until now, achieving the necessary high-efficiency, ultra-fine-pitch red pixels has proved a challenge.

Traditional red LEDs are largely based on aluminum indium gallium phosphide (AlInGaP) materials. This means they show a drastic efficiency drop as the device size decreases due to their large carrier diffusion lengths and high surface recombination velocity.

Porotech’s unique production process has enabled the creation of a new class of porous GaN semiconductor materials that is redefining what is possible. As a result, the company is now the first to launch a commercially available native red indium gallium nitride (InGaN) LED epiwafer for micro-LED applications.

“Micro-LED displays using GaN-based material technology are widely seen as the only technology that can deliver displays bright and efficient enough to meet the requirements of AR,” said Porotech CEO and co-founder Dr Tongtong Zhu. “With AR glasses expected to one day replace smartphones – or at least reduce our interaction with the devices in our pockets – development of advanced materials to improve performance is crucial.

“Integration of AlInGaP red and indium InGaN green and blue LED displays in a module with micron-scale pixels is extremely challenging as high surface recombination velocities in AlInGaP devices make this material unsuitable for efficient micro-LEDs. Our breakthrough extends the emission range of InGaN LEDs to meet the performance needs of the red display, whilst delivering the ability to scale wafer size required by micro-LED semiconductor display technology.”

GaN is a material poised to make an impact across electronics and optoelectronics – from efficient power transistors and lasers to quantum devices, sensors and solar cells – and the introduction of porous architectures can extend its capability in all these realms. Porotech’s product fits within existing industry standards and processes. The proprietary technology is robust but also flexible enough to be tailored to the needs of different applications. Porotech’s native red InGaN micro-LEDs have a wavelength of 640 nm at 10 A/cm2, and improved performance over conventional AlInGaP and colour-converted red at very small pixels and pitches.

Earlier this year, Porotech secured a £1.5 million seed round investment co-led by Cambridge Enterprise, the commercialisation arm of the University of Cambridge, and IQ Capital Partners, with the additional participation of Martlet Capital and a syndicate of angel investors from Cambridge Angels and Cambridge Capital Group.

ENDS

Notes for editors

Porotech is a gallium nitride (GaN) material technology developer and a spin-out from the Cambridge Centre for Gallium Nitride at the University of Cambridge. The company focuses on the development of high-performance and energy-efficient wide-bandgap compound GaN semiconductors by applying cutting-edge material technologies and solutions to unleash the full potential of GaN to revolutionise the electronics industry. For more information, visit: www.porotech.co.uk

Originally published here.

Categories: News

Tags: